Nektar Therapeutics (NASDAQ:NKTR) – Research analysts at Jefferies Group issued their FY2022 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Tuesday. Jefferies Group analyst D. Steinberg forecasts that the biopharmaceutical company will post earnings of ($0.67) per share for the year. Jefferies Group currently has a “Buy” rating and a $88.00 price target on the stock.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.16. The firm had revenue of $152.90 million for the quarter, compared to analyst estimates of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The business’s quarterly revenue was up 321.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.32) EPS.

Several other research analysts have also weighed in on NKTR. Mizuho began coverage on Nektar Therapeutics in a research report on Tuesday, September 26th. They set a “buy” rating and a $30.00 price target on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $80.00 price target (up previously from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Zacks Investment Research raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Roth Capital set a $45.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 13th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $44.00 price target on shares of Nektar Therapeutics in a research report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $42.50.

Nektar Therapeutics (NASDAQ:NKTR) traded up $0.76 during trading hours on Wednesday, hitting $70.16. The company’s stock had a trading volume of 1,430,416 shares, compared to its average volume of 2,260,000. The firm has a market cap of $11,050.00, a price-to-earnings ratio of -98.82 and a beta of 1.81. Nektar Therapeutics has a 52-week low of $11.41 and a 52-week high of $75.33. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99.

Several hedge funds have recently bought and sold shares of NKTR. Janus Henderson Group PLC acquired a new position in shares of Nektar Therapeutics during the 2nd quarter worth approximately $34,661,000. PointState Capital LP increased its holdings in shares of Nektar Therapeutics by 281.7% during the 2nd quarter. PointState Capital LP now owns 1,731,000 shares of the biopharmaceutical company’s stock worth $33,841,000 after acquiring an additional 1,277,500 shares during the last quarter. Rubric Capital Management LP acquired a new position in shares of Nektar Therapeutics during the 3rd quarter worth approximately $23,924,000. State Street Corp increased its holdings in shares of Nektar Therapeutics by 11.3% during the 2nd quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock worth $86,179,000 after acquiring an additional 447,023 shares during the last quarter. Finally, Numeric Investors LLC increased its holdings in shares of Nektar Therapeutics by 2,111.5% during the 2nd quarter. Numeric Investors LLC now owns 440,729 shares of the biopharmaceutical company’s stock worth $8,616,000 after acquiring an additional 420,800 shares during the last quarter. 96.01% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director Christopher A. Kuebler sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the transaction, the director now directly owns 70,500 shares of the company’s stock, valued at approximately $4,135,530. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Stephen K. Doberstein sold 396,323 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $29.00, for a total value of $11,493,367.00. Following the transaction, the senior vice president now directly owns 52,016 shares in the company, valued at $1,508,464. The disclosure for this sale can be found here. Insiders have sold a total of 614,017 shares of company stock worth $20,587,527 over the last three months. 6.10% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Nektar Therapeutics to Post FY2022 Earnings of ($0.67) Per Share, Jefferies Group Forecasts (NKTR)” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/18/nektar-therapeutics-to-post-fy2022-earnings-of-0-67-per-share-jefferies-group-forecasts-nktr.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.